Step counts may predict trouble during lung cancer therapy

NCT ID NCT04878952

Terminated Symptom relief Sponsor: NRG Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether monitoring daily step counts in people with stage III non-small cell lung cancer during chemoradiotherapy helps doctors provide better supportive care and reduce hospital stays or treatment delays. Only 3 participants were enrolled before the study was stopped early. The approach aimed to catch problems early by watching activity levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER STAGE III RECURRENT NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

WellSpan Health - Chambersburg

Chambersburg, Pennsylvania, 17201, United States
WellSpan Health - Ephrata

Ephrata, Pennsylvania, 17522, United States
WellSpan Health - Gettysburg

Gettysburg, Pennsylvania, 17325, United States
WellSpan Health - Lebanon

Lebanon, Pennsylvania, 17042, United States
WellSpan Health - York

York, Pennsylvania, 17403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.